Compare Enveric Biosciences Inc (ENVB) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Nomura Holdings Inc — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while Nomura Holdings Inc trades at $9.85 (market cap $29.38B). The key difference: Nomura Holdings Inc is far larger — about 5522.6× Enveric Biosciences Inc's market cap, and Nomura Holdings Inc pays a 3.23% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | NMR | |
|---|---|---|
Market Cap | $5.32M | $29.38B |
Sector | Health | Financials |
52-Week High | $17.40 | $10.04 |
52-Week Low | $1.28 | $6.30 |
Enterprise Value | $408.82K | — |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Nomura Holdings (NMR) trades at $9.75, up 1.35% with a bullish technical signal from moving averages. The company reported strong revenue growth to $1.66T in 2025 with a 20.49% net margin, though recent quarters show mixed earnings results with two misses. Analyst consensus leans Hold (66.7%) while technical indicators show RSI levels above 90 suggesting potential overbought conditions.
Outlook remains cautiously optimistic with valuation metrics appearing reasonable (P/E 13.65) and strategic expansion through acquisitions. Key risks include volatile cash flows, rising debt levels, and integration challenges from recent acquisitions. The stock presents value opportunity but requires monitoring of earnings consistency and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
